Advanced Search

Journal of Traditional Chinese Medicine >

2026 , Vol. 46 >Issue 2: 418 - 426

DOI: https://doi.org/10.19852/j.cnki.jtcm.2026.02.014

Original Articles

Efficacy and safety of Jiawei Simiaoyongan granules (加味四妙勇安颗粒) in the treatment of non-infectious anterior uveitis: a randomized open-label trial

  • SUN Wu ,
  • CHU Liqun ,
  • ZHOU Wanyu ,
  • SHI Hang ,
  • CHEN Shuiling ,
  • LIANG Yu ,
  • WU Jianguo ,
  • WEI Dong ,
  • LIU Yushen ,
  • ZHANG Qi
Expand
  • 1 Department of Ophthalmology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China
    2 Department of Encephalopathy, Dongzhimen Hospital, Beijing University of Chinese Medicine, Beijing 100007, China
ZHOU Wanyu, Department of Ophthalmology, Xiyuan Hospital of China Academy of Chinese Medical Sciences, Beijing 100091, China. zhouwylx@sina.com; Telephone: +86-10-62835138

Received date: 2025-02-07

  Accepted date: 2025-07-14

  Online published: 2026-04-04

Supported by

Capital Health Development Research Project: Research on the Treatment of Non-infectious Uveitis Based on Disease-Syndrome Combination”(2022-2-4174);Beijing Natural Science Foundation(7244501);Study on the Mechanism of Liangxue Sanjie Decoction in Treating Subretinal Fibrosis Secondary to Neovascular Age-related Macular Degeneration Based on miR155-mediated Autophagy”(82405489);Hospital Capability Enhancement Project of Xiyuan Hospital, China Academy of Chinese Medical Sciences: a Randomized Controlled Trial of Acupuncture with Huoxue Tongluo Therapy for Neovascular Age-related Macular Degeneration(XYZX0202-10)

Fold

Abstract

OBJECTIVE: To observe the clinical efficacy and safety of Chinese herbal medicine Jiawei Simiao Yongan granules (加味四妙勇安颗粒, JWSMYAG) in the treatment of non-infectious anterior uveitis (NIAU).

METHODS: We conducted a single-center, randomized, open-labeled clinical trial in adults with NIAU. Patients received standard treatment or a combination of JWSMYAG (twice daily) for three months, with a 3-month withdrawal period for observation. The primary endpoint was the recurrence rate within six months.

RESULTS: A total of 98 patients were included in the intention-to-treat analysis, including 49 patients in the Traditional Chinese Medicine (TCM) group and 49 patients in the control group. Compared with the control group, the number of relapses was significantly lower in the TCM group [24.5% vs6.1%, P = 0.0224; Hazard Ratio = 0.208, 95% Confidence Interval (0.059, 0.737)]; in addition, patients in the TCM group had lower symptom scores of eye pain, insomnia, and bitter taste within two weeks (all P < 0.05). There was no significant difference between the two groups in terms of the difference in best corrected visual acuity change over six months, the number of intraocular pressure elevations > 10 mm Hg, the scoring of anterior chamber cells, the number of patients with keratic precipitates (+) after 1/2 weeks of treatment, and the scores of conjunctival hyperemia, headache, photophobia, and lacrimation. The difference in the number of adverse events between the two groups over six months was not statistically significant.

CONCLUSION: JWSMYAG can reduce the recurrence rate of NIAU, alleviate ocular pain, insomnia, and bitter taste symptoms in patients with NIAU, and have a favorable safety profile.

Key words： non-infectious anterior uveitis; recurrence rate; safety; randomized controlled study; Jiawei Simiaoyongan granules

Cite this article

SUN Wu , CHU Liqun , ZHOU Wanyu , SHI Hang , CHEN Shuiling , LIANG Yu , WU Jianguo , WEI Dong , LIU Yushen , ZHANG Qi . Efficacy and safety of Jiawei Simiaoyongan granules (加味四妙勇安颗粒) in the treatment of non-infectious anterior uveitis: a randomized open-label trial[J]. Journal of Traditional Chinese Medicine, 2026 , 46(2) : 418 -426 . DOI: 10.19852/j.cnki.jtcm.2026.02.014

References

1. Rosenbaum JT, Bodaghi B, Couto C, et al. New observations and emerging ideas in diagnosis and management of non-infectious uveitis: a review. Semin Arthritis Rheum 2019; 49: 438-45.
2. Tsirouki T, Dastiridou A, Symeonidis C, et al. A Focus on the epidemiology of uveitis. Ocul Immunol Inflamm 2018; 26: 2-16.
3. Joltikov KA, Lobo-Chan AM. Epidemiology and risk factors in non-infectious uveitis: a systematic review. Front Med (Lausanne) 2021; 8: 695904.
4. Takeuchi M, Mizuki N, Ohno S. Pathogenesis of non-infectious uveitis elucidated by recent genetic findings. Front Immunol 2021; 12: 640473.
5. Espinosa G, Herreras JM, Mu?oz-Fernández S, García Ruiz de Morales JM, Cordero-Coma M. Recommendations statement on the immunosuppressive treatment of non-infectious, non-neoplastic, non-anterior uveitis. Med Clin (Barc) 2020; 155: 220. e1-12.
6. Reddy A, Liu SH, Brady CJ, Sieving PC, Palestine AG. Corticosteroid implants for chronic non-infectious uveitis. Cochrane Database Syst Rev 202329; 8: CD010469.
7. Zhao C, Zhang M. Immunosuppressive treatment of non-infectious uveitis: history and current choices. Chin Med Sci J 2017; 32: 48-61.
8. Jap A, Chee SP. Immunosuppressive therapy for ocular diseases. Curr Opin Ophthalmol 2008; 19: 535-40.
9. Pujari SS, Kempen JH, Newcomb CW, et al. Cyclophosphamide for ocular inflammatory diseases. Ophthalmology 2010; 117: 356-65.
10. Pasadhika S, Kempen JH, Newcomb CW, et al. Azathioprine for ocular inflammatory diseases. Am J Ophthalmol 2009; 148: 500-9.e2.
11. Ka?maz RO, Kempen JH, Newcomb C, et al. Cyclosporine for ocular inflammatory diseases. Ophthalmology 2010; 117: 576-84.
12. Okhravi N, Lightman S. Cystoid macular edema in uveitis. Ocul Immunol Inflamm 2003; 11: 29-38.
13. Agrawal H, Doan H, Pham B, et al. Systemic immunosuppressive therapies for uveitis in developing countries. Indian J Ophthalmol 2020; 68: 1852-62.
14. Murphy CC, Greiner K, Plskova J, et al. Cyclosporine vs tacrolimus therapy for posterior and intermediate uveitis. Arch Ophthalmol 2005; 123: 634-41.
15. Taylor DO, Barr ML, Radovancevic B, et al. A randomized, multicenter comparison of tacrolimus and cyclosporine immunosuppressive regimens in cardiac transplantation: decreased hyperlipidemia and hypertension with tacrolimus. J Heart Lung Transplant 1999; 18: 336-45.
16. Samson CM, Waheed N, Baltatzis S, Foster CS. Methotrexate therapy for chronic noninfectious uveitis: analysis of a case series of 160 patients. Ophthalmology 2001; 108: 1134-9.
17. Gangaputra S, Newcomb CW, Liesegang TL, et al. Methotrexate for ocular inflammatory diseases. Ophthalmology 2009; 116: 2188-98.e1.
18. Kremer JM, Alarcón GS, Lightfoot Jr RW, et al. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994; 37: 316-28.
19. Galor A, Jabs DA, Leder HA, et al. Comparison of antimetabolite drugs as corticosteroid-sparing therapy for noninfectious ocular inflammation. Ophthalmology 2008; 115: 1826-32.
20. Wu X, Tao M, Zhu L, Zhang T, Zhang M. Pathogenesis and current therapies for non-infectious uveitis. Clin Exp Med 2023; 23: 1089-106.
21. Agrawal R, Lee C, Phatak S, Pavesio C. Immunopharmacotherapy of non-infectious uveitis: where do we stand? Expert Opin Biol Ther 2014; 14: 1719-22.
22. Imrie FR, Dick AD. Biologics in the treatment of uveitis. Curr Opin Ophthalmol 2007; 18: 481-6.
23. Zhang DD, Yao J, Sun H, Wang JD, Cao CH. The advantages and characteristics of Chinese medicine in prevention and treatment of anterior uveitis. Zhong Guo Zhong Yi Yan Ke Za Zhi 2021; 31: 530-2.
24. Wei D, Zhang WD, Zhou WY. Clinical discussion on the treatment of uveitis with Si Miao Yong An Tang. Zhong Guo Zhong Yi Yan Ke Za Zhi 2020; 30: 741-4.
25. Fu S, Yu F, Sun T, Hu Z. Drug-drug interaction by metabolites: Challenges and solutions during therapeutics innovation. Drug Metab Dispos 2026; 54: 100251.
26. Xiao GS, Tang YZ. Encyclopedia of Ophthalmology of Traditional Chinese Medicine. Beijing: People's Medical Publishing House, 2011: 192-5.
27. Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016; 388: 1183-92.
28. Jabs DA, Nussenblatt RB, Rosenbaum JT; Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005; 140: 509-16.
29. Zou J, Xu W, Li Z, et al. Network pharmacology-based approach to research the effect and mechanism of Si-Miao-Yong-An decoction against thromboangiitis obliterans. Ann Med 2023; 55: 2218105.
30. Li HY, Sun H, Zhang AH, et al. Therapeutic effect and mechanism of Si-Miao-Yong-An-Tang on thromboangiitis obliterans based on the urine metabolomics approach. Front Pharmacol 2022; 13: 827733.
31. Zhang S, Shao Y, Jin R, Ma B. Combining Network pharmacology, molecular docking, molecular dynamics simulation, and experimental validation to uncover the efficacy and mechanisms of Si-Miao-Yong-An decoction in diabetic wound healing. J Inflamm Res 2025; 18: 4087-101.
32. Zhou WY, Fang DY. Treatment of uveitis from collateral disease. Zhong Yi Za Zhi 2009; 50: 977-8.
33. Yu LM. Clinical study of Simiaoyong’an decoction in the treatment of anterior uveitis. Henan Zhong Yi 2017; 37: 287-9.
34. Zhou WY, Wang WX, Fang DY. Fang Dingya’s experience in treating leukoaraiosis-related uveitis by staging using the theory of collateral disease. Zhong Yi Za Zhi 2021; 62: 1116-9.
35. Takeuchi M, Usui Y, Namba K, et al. Ten-year follow-up of infliximab treatment for uveitis in Beh?et disease patients: a multicenter retrospective study. Front Med 2023; 10: 1095423.
36. Miao M, Xiang L. Pharmacological action and potential targets of chlorogenic acid. Adv Pharmacol 2020; 87: 71-88.
37. Naveed M, Hejazi V, Abbas M, et al. Chlorogenic acid (CGA): a pharmacological review and call for further research. Biomed Pharmacother 2018; 97: 67-74.
38. Wang JZ, Zhang YF, Xu F, Shang MY, Liu GX, Cai SQ. Investigation of the in vivo metabolism of harpagoside and distribution of its metabolites in rats by HPLC-IT-TOF-MSn. Biomed Chromatogr 2018; 32: e4218.
39. Kim JY, Cheon YH, Ahn SJ, et al. Harpagoside attenuates local bone Erosion and systemic osteoporosis in collagen-induced arthritis in mice. BMC Complement Med Ther 2022; 22: 214.
40. Che D, Cao J, Liu R, et al. Harpagoside-induced anaphylactic reaction in an IgE-independent manner both in vitro and in vivo. Immunopharmacol Immunotoxicol 2018; 40: 173-8.
41. Kowalska A, Kalinowska-Lis U. 18β-Glycyrrhetinic acid: its core biological properties and dermatological applications. Int J Cosmet Sci 2019; 41: 325-31.
42. Ke P, Yong L, Zhe L, Guang F. Mechanisms of Baishao (Radix Paeoniae Alba) and Gancao (Radix Glycyrrhizae) on major depressive disorder: network pharmacology and in vivo validation. J Tradit Chin Med 2025; 45: 1067-77.
43. Li H, You J, Yang X, et al. Glycyrrhetinic acid: a potential drug for the treatment of COVID-19 cytokine storm. Phytomedicine 2022; 102: 154153.
Options
Outlines

/

〈 〉